FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by α1(IV)NC1

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4567-4575

  Boosani, Chandra S ^a,b   Nalabothula, Narasimharao ^a,b   Munugalavadla, Veerendra ^c   Cosgrove, Dominic ^d   Keshamoun, Venkateshwar G ^e   Sheibani, Nader ^f   Sudhakar, Akulapalli ^a,f,g  

^a Cell Signaling and Tumor Angiogenesis Laboratory   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; COLLAGEN TYPE 4; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2; PROTEIN BCL XL; RECOMBINANT ANTIGEN; RECOMBINANT RETINA S ANTIGEN; THYMIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; BCL2L1 PROTEIN, MOUSE; CASP3 PROTEIN, MOUSE; EPITOPE; FOCAL ADHESION KINASE 1; PARP1 PROTEIN, MOUSE; PROTEIN BCL X; PTK2 PROTEIN, MOUSE; RECOMBINANT PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL SELECTION; CELL STIMULATION; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN CLEAVAGE; QUANTITATIVE ANALYSIS; RETINA CELL; RETINA ENDOTHELIAL CELL; RETINA NEOVASCULARIZATION; ANIMAL; CELL MOTION; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; RETINA BLOOD VESSEL; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE IV; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EPITOPES; FLOW CYTOMETRY; FOCAL ADHESION KINASE 1; MICE; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349572805     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3473     Document Type: Article

References (49)

1. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
2. Garner A. Ocular angiogenesis. Int Rev Exp Pathol. 1986;28:249-306.
3. Jampol LM, Ebroon DA, Goldbaum MH. Peripheral proliferative retinopathies: an update on angiogenesis, etiologies and management. Surv Ophthalmol. 1994;38:519-540.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
5. Takahashi H, Tamaki Y, Ishii N, et al. Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Curr Eye Res. 2008;33:1002-1010.
6. Deissler HL, Lang GE. [Effect of VEGF165 and the VEGF aptamer pegaptanib (Macugen) on the protein composition of tight junctions in microvascular endothelial cells of the retina]. Klin Monatsbl Augenheilkd. 2008;225:863-867.
7. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol. 1992;27:93-127.
8. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest. 1988;59:44-51.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
10. Maragoudakis ME, Missirlis E, Karakiulakis GD, Sarmonica M, Bastakis M, Tsopanoglou N. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int. 1993;43:147-150.
11. Pedchenko V, Zent R, Hudson BG. Alpha (v) beta3 and alpha (v) beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. J Biol Chem. 2004;279:2772-2780.
12. Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 2000;60: 2520-2526.
13. Sudhakar A, Nyberg P, Keshamouni VG, et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest. 2005;115:2801-2810.
14. Su X, Sorenson CM, Sheibani N. Isolation and characterization of murine retinal endothelial cells. Mol Vis. 2003;9:171-178.
15. Borza CM, Pozzi A, Borza DB, et al. Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant inhibitor for integrin alphavbeta3. J Biol Chem. 2006;281: 20932-20939.
16. Boosani CS, Sudhakar A. Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells. Protein Expr Purif. 2006;49:211-218.
17. Chow J, Ogunshola O, Fan SY, Li Y, Ment LR, Madri JA. Astrocytederived VEGF mediates survival and tube stabilization of hypoxic brain microvascular endothelial cells in vitro. Brain Res Dev Brain Res. 2001;130:123-132.
18. Boosani CS, Mannam AP, Cosgrove D, et al. Regulation of COX-2 mediated signaling by 3 type IV noncollagenous domain in tumor angiogenesis. Blood. 2007;110:1168-1177.
19. Munugalavadla V, Borneo J, Ingram DA, Kapur R. p85alpha subunit of class IA PI-3 kinase is crucial for macrophage growth and migration. Blood. 2005;106:103-109.
20. Kohler C, Orrenius S, Zhivotovsky B. Evaluation of caspase activity in apoptotic cells. J Immunol Methods. 2002;265:97-110.
21. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001;20:4995-5004.
22. Bagley RG, Walter-Yohrling J, Cao X, et al. Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res. 2003;63:5866-5873.
23. McCawley LJ, Matrisian LM. Tumor progression: defining the soil round the tumor seed. Curr Biol. 2001;11:R25-R27.
24. Huang Q, Sheibani N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol. 2008;295:C1647-C1657.
25. Folkman J, Haudenschild C. Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc UK. 1980;100:346-353.
26. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene. 1998;17:3237-3245.
27. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995;268:233-239.
28. Roberts MS, Woods AJ, Shaw PE, Norman JC. ERK1 associates with alpha vbeta 3 integrin and regulates cell spreading on vitronectin. J Biol Chem. 2003;278:1975-1985.
29. Furuta Y, Ilic D, Kanazawa S, Takeda N, Yamamoto T, Aizawa S. Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK. Oncogene. 1995;11:1989-1995.
30. Cary LA, Han DC, Polte TR, Hanks SK, Guan JL. Identification of p130Cas as a mediator of focal adhesion kinase- promoted cell migration. J Cell Biol. 1998;140:211-221.
31. Becker PM, Verin AD, Booth MA, Liu F, Birukova A, Garcia JG. Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1500-L1511.
32. Kuo CJ, LaMontagne KR Jr, Garcia-Cardena G, et al. Oligomerization- dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol. 2001;152: 1233-1246.
33. Grethe S, Ares MP, Andersson T, Porn-Ares MI. p38 MAPK mediates TNF-induced apoptosis in endothelial cells via phosphorylation and downregulation of Bcl-x(L). Exp Cell Res. 2004;298:632-642.
34. Sudhakar A, Boosani CS. Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen. Gene Regulation Syst Biol. 2007;1:217-226.
35. Nyberg P, Xie L, Sugimoto H, et al. Characterization of the antiangiogenic properties of arrestin, an α1 β1 integrin-dependent collagen- derived tumor suppressor. Exp Cell Res. 2008;314:3292-3305.
36. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706-1709.
37. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
38. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
39. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
40. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151:281-291.
41. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci. 1998;39: 180-188.
42. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.
43. Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica. 2008;222:321-323.
44. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247:311-318.
45. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008;28:2027-2031.
46. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IVadministered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:1522.e1521-1522.e1514.
47. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vectordelivered pigment epithelium-derived factor for neovascular agerelated macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17:167-176.
48. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol. 2009;247:171-177.
49. Lima ESR, Kachi S, Akiyama H, et al. Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis. J Cell Physiol. 2006;208: 161-166.